1h Free Analyst Time
The Clinical Chemistry & Immunodiagnostic Market grew from USD 37.67 billion in 2023 to USD 40.01 billion in 2024. It is expected to continue growing at a CAGR of 6.41%, reaching USD 58.20 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
Clinical chemistry involves studying the chemical and biochemical phenomena in the body, while immunodiagnostics is concerned with identifying disease markers through immune system responses. The expansion in clinical chemistry and immunodiagnostic testing is driven by factors such as an aging global population, which increases the prevalence of chronic diseases requiring ongoing monitoring. Furthermore, growing awareness of preventive healthcare has increased routine screenings, fueling the need for these tests. However, challenges in this sector include maintaining high standards of accuracy and reliability, as the results directly impact patient care. Additionally, the cost of developing and sustaining advanced testing technologies can be a barrier to entry in some markets. Despite these challenges, the potential for developing tests that are more tailored to individual genetic profiles can predict diseases more accurately. Advances in technology and automation, which enhance the speed and accuracy of tests, are expected to open up new growth avenues for market players.
Regional Insights
In the Americas, the clinical chemistry and immunodiagnostics market shows robust growth, driven primarily by technological advancements in diagnostic techniques and a strong emphasis on healthcare infrastructure. The United States, in particular, exhibits significant adoption of these techniques owing to increasing health awareness and the prevalence of chronic diseases that requires ongoing monitoring and diagnostic tests. European countries are observing steady growth in global clinical chemistry and immunodiagnostics owing to well-established healthcare systems and high healthcare spending. Increased efforts to enhance healthcare infrastructure and investments in health technology across the Middle East and Africa show the growth potential. Asia-Pacific is witnessing the fastest growth, with rapidly developing healthcare sectors in countries such as Australia, China, and India, increased healthcare spending, and rising awareness of preventive healthcare measures. Moreover, the expanding middle-class population and government initiatives towards health insurance coverage are contributing factors to the growth in this market.Market Insights
Market Dynamics
- The market dynamics represent an ever-changing landscape of the Clinical Chemistry & Immunodiagnostic Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
Market Drivers
- Rising elderly population and growing prevalence of chronic diseases
- Favorable government initiatives for adoption of clinical chemistry & immunodiagnostic techniques
- Growing importance and awareness of point-of-care testing
Market Restraints
- Issues associated with chemistry and immunodiagnostic product recall
Market Opportunities
- Ongoing technological advancements in clinical chemistry and immunodiagnostic instruments
- Growing potential of clinical chemistry & immunodiagnostic in telemedicine and personalized therapies
Market Challenges
- Stringent and varying regulatory standards for product development and commercialization
Market Segmentation Analysis
- Product Type: Adoption of modular and scalable systems that easily integrate with existing hospital information systems
- End-user: Growing focus on advanced technological integration in instruments
Industry Insights
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Clinical Chemistry & Immunodiagnostic Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Clinical Chemistry & Immunodiagnostic Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Recent Developments
Introduction of Beckman Coulter's DxC 500 AU Chemistry Analyzer
Beckman Coulter Diagnostics is set to introduce the DxC 500 AU Chemistry Analyzer at Medlab Middle East in Dubai. This innovative clinical chemistry analyzer enhances the functionality of satellite and independent hospital laboratories, aligning with the evolving hub-and-spoke models utilized by global healthcare systems for improved efficiency and service accessibility. The DxC 500 AU boasts a compelling set of features, including a comprehensive assay menu exceeding 120 tests, advanced automation, guided workflows, and standardized reagents.Strategic Partnership Between Fujirebio Holdings and Agappe Diagnostics to Revolutionize Chemiluminescence Immunoassay Production in India
Fujirebio Holdings and Agappe Diagnostics from Kochi, India, are set to enhance the immunoassay sector through a pivotal Contract Development and Manufacturing Organization (CDMO) partnership. This collaboration entails the local production of cartridge-based chemiluminescence immunoassay (CLIA) reagents for the Mispa i60 and Mispa i121 analyzers, marking it as the first instance of an Indian company manufacturing complete chemiluminescence solutions domestically.Roche Expands Diagnostics Portfolio with Acquisition of LumiraDx Point of Care Technology
F. Hoffmann-La Roche Ltd. has entered into a definitive agreement to acquire specific segments of LumiraDx, focusing on its innovative Point of Care (POC) technology. This acquisition integrated into Roche Diagnostics, enhancing its capability to provide immediate testing services in various healthcare settings globally. LumiraDx's technology, praised for its versatility and performance across multiple disease areas, is pivotal in decentralizing rapid diagnostic access, enabling quicker patient results independent of location. Roche aims to utilize this technology across healthcare pathways ranging from homes to intensive care units, leveraging their worldwide network to enhance access to essential diagnostic tests.Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Clinical Chemistry & Immunodiagnostic Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.Key Company Profiles
The report delves into recent significant developments in the Clinical Chemistry & Immunodiagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accurex Biomedical Private Limited, Agappe Diagnostics Ltd., Bio-Rad Laboratories, Inc., bioMérieux SA, Cardinal Health, Inc., Chengdu Seamaty Technology Co., Ltd., Danaher Corporation, DiaSorin S.p.A, ELITechGroup by Bruker Corporation, F. Hoffmann-La Roche Ltd., GenviewDX, H.U. Group Holdings Inc., Hitachi, Ltd., HORIBA, Ltd., Immuno Diagnostics Pvt. Ltd., Medix Biochemica AB, QIAGEN N.V., Quest Diagnostics Incorporated, QuidelOrtho Corporation, Sekisui Medical Co. Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens AG, Thermo Fisher Scientific Inc., and viSole The Solution.Market Segmentation & Coverage
This research report categorizes the Clinical Chemistry & Immunodiagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:Product Type
- Instruments
- Reagents
End-user
- Diagnostic Laboratories
- Hospitals
Region
Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Purchase of this report includes 1 year online access with quarterly updates
Purchase of this report includes 1 year online access with quarterly updates
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Table of Contents
1. Preface
2. Research Methodology
5. Market Insights
6. Clinical Chemistry & Immunodiagnostic Market, by Product Type
7. Clinical Chemistry & Immunodiagnostic Market, by End-user
8. Americas Clinical Chemistry & Immunodiagnostic Market
9. Asia-Pacific Clinical Chemistry & Immunodiagnostic Market
10. Europe, Middle East & Africa Clinical Chemistry & Immunodiagnostic Market
11. Competitive Landscape
12. Competitive Portfolio
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Accurex Biomedical Private Limited
- Agappe Diagnostics Ltd.
- Bio-Rad Laboratories, Inc.
- bioMérieux SA
- Cardinal Health, Inc.
- Chengdu Seamaty Technology Co., Ltd.
- Danaher Corporation
- DiaSorin S.p.A
- ELITechGroup by Bruker Corporation
- F. Hoffmann-La Roche Ltd.
- GenviewDX
- H.U. Group Holdings Inc.
- Hitachi, Ltd.
- HORIBA, Ltd.
- Immuno Diagnostics Pvt. Ltd.
- Medix Biochemica AB
- QIAGEN N.V.
- Quest Diagnostics Incorporated
- QuidelOrtho Corporation
- Sekisui Medical Co. Ltd.
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Siemens AG
- Thermo Fisher Scientific Inc.
- viSole The Solution
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 186 |
| Published | June 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 40.01 Billion |
| Forecasted Market Value ( USD | $ 58.2 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
